Clinical reminders to providers of patients with reduced left ventricular ejection fraction increase defibrillator

Anurag Gupta1, Parisa Gholami, Mintu P Turakhia

  • 1Medical Service, VA Palo Alto Health Care System, Palo Alto, CA.

Circulation. Heart Failure
|December 10, 2013
PubMed

Insights

A simple provider reminder significantly increased referrals for implantable cardioverter defibrillators (ICDs) in eligible patients. This intervention improved both referral rates and documented discussions for ICD implantation.

Area of Science:

  • Cardiology
  • Medical Informatics
  • Healthcare Quality Improvement

Background:

  • Many patients eligible for implantable cardioverter defibrillators (ICDs) are not referred for implantation.
  • Provider referral rates for ICDs can be suboptimal.
  • Identifying and addressing barriers to ICD referral is crucial for patient care.

Purpose of the Study:

  • To evaluate if a simple provider reminder can increase referrals for implantable cardioverter defibrillators (ICDs).
  • To assess the impact of an electronic medical record-based intervention on ICD referral rates.
  • To determine if provider reminders improve documented discussions about ICD candidacy.

Main Methods:

  • Consecutive patients with left ventricular ejection fraction ≤35% were identified.
  • Patients were randomized to either a provider reminder or no intervention.
  • Referral for ICD implantation and documented discussion of candidacy were primary and secondary outcomes.

Main Results:

  • A provider reminder intervention increased ICD referral rates from 2% to 24% (P=0.004).
  • The intervention also improved documented discussions regarding ICD candidacy, rising from 44% to 67% (P=0.05).
  • The study involved 89 patients randomized after exclusions.

Conclusions:

  • A simple electronic medical record-based reminder to providers effectively increased ICD referral rates.
  • Provider-directed interventions can improve the utilization of life-saving therapies like ICDs.
  • This highlights a scalable method for enhancing patient access to appropriate cardiac device therapy.
Abstract

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626